Loading clinical trials...
Loading clinical trials...
Multicenter, Randomized, Open-label Clinical Trial to Compare Anidulafungin Versus Amphotericin B Safety in High Risk Hepatic Transplant Recipients
The study is a randomized, open-label safety study comparing the use of anidulafungin (200 mg i.v. as initial dose and 100 mg/d i.v. in subsequent doses) vs liposomal amphotericin B (3 mg/kg/d i.v.) in hepatic transplant recipients who have high risk of fungal infection.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Hospital Reina Sofia
Córdoba, Córdoba, Spain
Complexo Hospitalario de A Coruña
A Coruña, Spain
Hospital Clinic i Provincial
Barcelona, Spain
Hospital de Bellvitge
Barcelona, Spain
Hospital Vall d'Hebrón
Barcelona, Spain
Hospital de Cruces
Bilbao, Spain
Hospital Doce de Octubre
Madrid, Spain
Hospital Gregorio Marañón
Madrid, Spain
Hospital Ramón y Cajal
Madrid, Spain
Hospital Carlos Haya
Málaga, Spain
Start Date
November 1, 2011
Primary Completion Date
May 1, 2014
Completion Date
May 1, 2014
Last Updated
May 30, 2014
61
ACTUAL participants
Anidulafungin
DRUG
Liposomal amphotericin B
DRUG
Lead Sponsor
Fundacion SEIMC-GESIDA
Collaborators
NCT07480057
NCT07237750
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06181409